+

WO2003030909A1 - 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer - Google Patents

2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer Download PDF

Info

Publication number
WO2003030909A1
WO2003030909A1 PCT/US2002/030616 US0230616W WO03030909A1 WO 2003030909 A1 WO2003030909 A1 WO 2003030909A1 US 0230616 W US0230616 W US 0230616W WO 03030909 A1 WO03030909 A1 WO 03030909A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
group
compound
optionally substituted
hydrogen
Prior art date
Application number
PCT/US2002/030616
Other languages
English (en)
Inventor
Dhanapalan Nagarathnam
Chunguang Wang
Yuanwei Chen
Lin Yi
Jianqing Chen
Olaf Weber
Stephen Boyer
Roger B. Clark
Barton Phillips
Jennifer Burke
Gaetan Ladouceur
Cheng Bi
Michael J. Burke
James Cook
Sharad K. Verma
Jianmei Fan
Original Assignee
Bayer Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corporation filed Critical Bayer Pharmaceuticals Corporation
Publication of WO2003030909A1 publication Critical patent/WO2003030909A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to certain multi-ring compounds, particularly to compounds that are useful as inhibitors of kinases such as, but not limited to, serine/threonine kinases.
  • the present invention also relates to pharmaceutical compositions comprising the compounds of the present invention, as well as methods of using the compounds in inhibiting the kinases and treating patients suffering from diseases caused by various altered kinases.
  • the invention also relates to a method of producing the compounds of the present invention.
  • the present invention relates to intermediates used to prepare the compounds of the present invention.
  • serine/threonine protein kinases are involved in cellular signaling mechanisms that regulate gene expression and cell proliferation (Su and Karin, Curr. Opinion. Immunol. (1996), 8:402; Kolch, Biochem. J. (2000) 351:289).
  • Some serine/threonine kinases, such as cyclin dependent kinases (CDK) are necessary to progress from one step in the cell cycle to the next (Meyerson et al., EMBO J. (1992) 11 :2909). They are active when specifically bound to other cell cycle proteins (cyclin family). Changes in their activities or in the activities of their activators or inhibitors are common in cancerous cells (Motokura and Arnold, Biochim. Biophys.
  • Apoptosis is an intrinsic process present in all cells that can be regulated by extrinsic factors such as hormones, growth factors, cell surface receptors or cellular stress.
  • extrinsic factors such as hormones, growth factors, cell surface receptors or cellular stress.
  • the actions of both pro- and anti-apoptotic factors are often affected by modulation of the phosphorylation state of key elements of the apoptotic process.
  • Evidence has been accumulated that serine/threonine kinases are also involved directly in the regulation of the apoptotic cascade (Cross et al., Experimental Cell Research (2000) 256:34).
  • Viruses are by definition unable to replicate on their own but must enter a host cell in order to use the host cell's macromolecular machinery to replicate (Knipe in: Fields et al., Virology. Third Edition (Lippincott-Raven, 1996), p. 273. Inhibition of protein kinases has also shown encouraging results in controlling viral infections such as infections with human cytomegaloviruses (Bresnahan et al.,
  • the present invention relates to certain multi-ring compounds represented by the Formula (I):
  • each R 5 is independently an optionally substituted -Y (n) -mono-ring group or an optionally substituted -Y ( n ) -multi-ring group, said ring groups in each case containing 4-18 atoms in the ring and optionally containing 1-4 heteroatoms selected from the group consisting of N, S, and O; wherein n is 0 or 1 , and -Y- is selected from the group consisting of straight- or branched-chain C 2-3 -alky
  • each R 6 is independently hydrogen or alkyl
  • each R 8 and R 9 is independently hydrogen, optionally substituted C ⁇ -5 - alkyl, optionally substituted aryl, or optionally substituted arylalkyl, wherein said substitution is selected from the group consisting of optionally substituted alkyl, wherein said substitution on said alkyl is selected from the group consisting of fluoro and dialkylamino; and pharmaceutically acceptable salts and prodrugs thereof.
  • each X individually is -NR 1 R 6 , -NR 4 R 5 , or R 4 , with the proviso that at least one X is -NR 1 R 6 ; each R 1 is independently an optionally substituted moiety selected from the group consisting of indazolyl, quinolinyl, benzothiazolyl, benzotriazolyl, or benzoxazolyl, wherein said substitution is selected from the group consisting of hydrogen, methyl, and ethyl; R 2 is halo or optionally substituted alkyl, wherein said substitution is selected from the group consisting of fluoro, -COOR 8 , -COOR 9 , and -CONR 8 R 9 ; R 3 is hydrogen or methyl; each R 4 is hydrogen, methyl, phenyl, aryl, benzothiophenyl, pyridyl, indolyl, naphthalenyl, biphenyl, in
  • the present invention also relates to compounds of Formula (1-1)
  • each R 1 is independently 5-indazolyl, 6-indazolyl, 5-benzotriazolyl, 5- benzothiazolyl, 6-quinolinyl, 5-(1-methyl)indazolyl, 6-(1- methyl)indazolyl, 5-(1-ethyl)indazolyl, 6-(1-ethyl)-indazolyl, 3- quinolyl, or 3-isoquinolyl;
  • R 2 is hydrogen, fluoro, bromo, chloro, methyl, or trifluoromethyl;
  • R 3 is hydrogen or methyl, and pharmaceutically acceptable salts and prodrugs thereof.
  • the present invention also relates to compounds of Formula (I-2)
  • each R 1 is independently 5-indazolyl, 6-indazolyl, 5-benzotriazolyl, 5- benzothiazolyl, 6-quinolinyl, 5-(1-methyl)indazolyl, 6-(1- methyl)indazolyl, 5-(1-ethyl)indazolyl, 6-(1-ethyl)-indazolyl, 3- quinolyl, or 3-isoquinolyl;
  • R 2 is hydrogen, fluoro, bromo, chloro, methyl, or trifluoromethyl;
  • R 3 is hydrogen or methyl
  • R 4 is hydrogen or methyl
  • the present invention also relates to compounds of Formula (I-3)
  • R 1 is 5-quinolyl or 6-quinolyl;
  • R 2 is fluoro or trifluoromethyl; and
  • R 4 is optionally substituted phenyl or pyridyl, wherein said substitution is selected from the group consisting of halo, amino, hydroxy, acetyl, alkyl, alkoxy, alkenyl, hydroxyalkyl, dialkylamino, and phenyl; and pharmaceutically acceptable salts and prodrugs thereof.
  • the present invention also relates to the compounds of Formula (1-4)
  • R 1 is independently 5-indazolyl, 6-indazolyl, 5-benzotriazolyl, 5- benzothiazolyl, 6-quinolinyl, 5-(1-methyl)indazoIyI, 6-(1- methyl)indazolyl, 5-(1-ethyl)indazolyl, 6-(1-ethyl)-indazolyl, 3- quinolyl, or 3-isoquinolyl;
  • R 2 is hydrogen, fluoro, chloro, bromo, methyl, or trifluoromethyl;
  • R 3 is hydrogen or methyl;
  • R 4 is hydrogen or methyl
  • R 5 is an optionally substituted -Y(n)-moiety, wherein n is 0 or 1 , Y is selected from the group consisting of straight- or branched-chain
  • C 2 _ 3 -alkylenyl, -N CH, and -N-CHCH 3 , and said moiety is selected from the group consisting of cycloalkyl, phenyl, naphthyl, pyridyl, thienyl, furyl, quinolinyl, benzothiophenyl, benzothiazolyl, indol-3-yl, and quinoline-4-thio, said substitution being selected from the group consisting of methyl, ethyl, fluoro, bromo, chloro, trifluoromethyl, methoxyl, methylenedioxyl, sulfonamidyl, morpholinyl, and - pyrazinyl; and and pharmaceutically acceptable salts and prodrugs thereof.
  • the present invention also relates to compounds of Formula (I-5)
  • R >1 is 5-indazolyl, 6-indazolyl, 5-benzotriazolyl, 5-benzothiazolyl, 6- quinolinyl, 5-(1-methyl)indazolyl, 6-(1-methyl)indazolyl, 5-(1- ethyi)indazolyl, 6-(1-ethyl)-indazolyI, 3-quinolyl, or 3-isoquinolyl;
  • R 2 is hydrogen, fluoro, methyl, bromo, chloro, trifluoromethyl, -C0 2 CH 3 ,
  • R 3 is hydrogen or methyl
  • Another aspect of the present invention relates to pharmaceutical composition containing at least one of the compounds of the present invention.
  • the present invention also relates to a method for inhibiting kinases such as serine/threonine kinases in a warm-blooded animal in need thereof by administering at least one of the compounds of the present invention in an amount sufficient to inhibit said kinases.
  • kinases such as serine/threonine kinases
  • the present invention also relates to a method for treating a CDK- dependent disorder or disease in a warm-blooded animal in need of same, by administering to said animal at least one of the compounds of the present invention in an amount sufficient to inhibit CDK.
  • the present invention further relates to a method for inhibiting cellular proliferation in a warm-blooded animal in need thereof by administering to said animal at least one of the compounds of the present invention in an amount sufficient to inhibit said proliferation.
  • the present invention also relates to methods of treating a warm-blooded animal suffering from cancer or neoplastic disease by administering to said warmblooded animal an effective amount of at least one of the compounds of the present invention.
  • a still further aspect of the present invention relates to a method for modulating apoptosis in a warm-blooded animal in need thereof by administering at least one of the compounds of the present invention in an amount sufficient to modulate apoptosis.
  • the present invention relates to intermediates used to prepare the above compounds of the present invention. Still other objects and advantages of the present invention will become readily apparent by those skilled in the art from the following detailed description, wherein are shown and described preferred embodiments of the invention, simply by way of illustration of the best mode contemplated of carrying out the invention. As will be realized, the invention is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, without departing from the invention. Accordingly, the description is to be regarded as illustrative in nature and not as restrictive.
  • alkyl when used alone or as part of another term, refers to straight- or branched-chain optionally substituted hydrocarbon groups containing 1 to 6 carbon atoms; or optionally substituted cycloalkyl groups.
  • suitable straight-chain alkyl groups include methyl, ethyl and propyl.
  • Examples of branched-chain alkyl groups include isopropyl and t-butyl.
  • the preferred alkyl group is methyl.
  • the cycloalkyl groups typically contain 3-6 atoms in the ring and can include up to 2 heteroatoms such as N, S and O, and can include unsaturation in the ring.
  • Typical cycloalkyl groups and cycloalkyl groups containing hetero atoms in the ring include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, 2-pyrrolinyl, imidazolidinyl, 2- imidazolinyl, pyrazolidinyl, 3-pyrazolyl, piperidinyl, piperazinyl and morpholinyl.
  • alkenyl refers to straight- or branched-chain optionally substituted hydrocarbon groups containing 2 to 6 carbon atoms comprising one carbon-carbon double bond. Examples of suitable alkenyl groups are methenyl and ethenyl.
  • alkoxy refers to straight- or branched-chain optionally substituted Ci-C 6 -alkyl-0-, wherein “alkyl” is as defined above.
  • dialkylamino refers to a nitrogen atom substituted with two alkyl groups, each alkyl being independently as defined above.
  • Suitable halo groups are chloro, bromo and fluoro.
  • An example of a fluoro substituted alkyl is trifluoromethyl.
  • at least one of R 2 or R 3 is alkyl substituted with either halo or halo-substituted alkyl , and most preferably one of R 5 or R 3 is alkyl substituted with either halo or halo-substituted alkyl and the other of R 5 or R 6 is hydrogen.
  • hydroxyalkyl refers to an alkyl as defined above substituted with at least one hydroxy group.
  • fused bicyclic unsaturated ring groups are 2-quinolinyl, 3- quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl, 1 -isoquinolinyl, 3-isoquinolinyl, 6- isoquinolinyl, 7-isoquinolinyl, 3-cinnolyl, 6-cinnolyl, 7-cinnoIyl, 2-quinazoIinyl, 4- quinazolinyl, 6-quinazolinyl, 7-quinazolinyl, 2-quinoxalinyI, 5-quinoxalinyl, 6- quinoxalinyl, 1-phthalazinyl, 6-phthalazinyl, 1 ,5-naphthyridin-2-yl, 1 ,5-naphthyridin- 3-yl, 1 ,6-naphthyridin-3-yl, 1 ,6-naphthyl
  • Substitutions for each of the fused ring groups are selected from the group consisting of -NR 8 R 9 , -OR 8 , fluoro, methenyl and ethenyl.
  • mono- and multi-ring groups include aryl and bicyclic fused aryl-cycloalkyl groups.
  • the aryl groups include an aromatic substituent which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently, directly or via a linker, e.g. methylene, O, S, N, -NR 8" S0 2 -, -COR 8 , -NR 8 CO- , and -S0 2 -NR 8 .
  • the rings may each contain from zero to four heteroatoms selected from N, O and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quatemized.
  • aryl groups include phenyl, 1 -naphthyl, 2-naphthyl, biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2- thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3- pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyr
  • -NR 8 S0 2 R 9 , -S0 2 R 8 , -S0 2 NR 8 R 9 , -NR 8 CONR 9 , -SR 8 , -NR 8 S0 2 , -OR 8 NR 8 R 9 , -N CR 8 , and optionally substituted alkyl wherein said substitutions on said alkyl are selected from the group consisting of -NR 8 R 9 , -OR 8 , fluoro, methenyl, and ethenyl.
  • the "bicyclic fused aryl-cycloalkyl" groups are those groups in which an aryl ring (or rings) is fused to a cycloalkyl group (including cycloheteroalkyl groups).
  • the group can be attached to the remainder of the molecule through either an available valence on the aryl portion of the group, or an available valence on the cycloalkyl portion of the group.
  • Examples of such bicyclic fused aryl-cycloalkyl groups are indanyl, benzotetrahydrofuranyl, benzotetrahydropyranyl and 1 ,2,3,4- tetrahydronaphthyl.
  • a substituted moiety When a substituted moiety is employed, it can be substituted at one or more positions with at least one of the above disclosed groups up to the number of available positions, but typically contain 1-3 substitutions, when substituted. When more than one substitution is present, the same or different substitution groups can be employed.
  • Pharmaceutically acceptable salts of the compounds of the above formulae include those derived from pharmaceutically acceptable, inorganic and organic acids and bases.
  • suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicyclic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, trifluoroacetic and benzenesulfonic acids.
  • Salts derived from appropriate bases include alkali such as sodium and ammonia or a salt with an organic base which affords a physiologically acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • the compounds of the formula (I) may be administered in the form of a pro- drug which is broken down in the human or animal body to give a compound of the formula (I).
  • pro-drugs include in vivo hydrolysable esters of a compound of the formula (I).
  • An in vivo hydrolyzable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolyzed in the human or animal body to produce the parent acid or alcohol.
  • Suitable pharmaceutically acceptable esters for carboxy include C 1-6 - alkoxymethyl esters, for example methoxymethyl; C ⁇ -6 -a!kanoyloxymethy!
  • esters for example pivaloyloxymethyl; phthalidyl esters; C 3 - 8 -cycloalkoxycarbonyloxy, C- ⁇ - 6 -alkyl esters, for example 1-cyclohexylcarbonyloxyethyl; 1 ,3-dioxolen-2- onylmethyl esters, for example 5-methyl-1 ,3-dioxolen-2-onylmethyl; and C-i -6 - alkoxycarbonyloxyethyl esters, for example 1-methoxycarbonyloxyethyl, and may be formed at any carboxy group in the compounds of this invention.
  • An in vivo hydrolyzable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and ⁇ - acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • inorganic esters such as phosphate esters and ⁇ - acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • ⁇ -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy- methoxy.
  • a selection of in vivo hydrolyzable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N- (dialkylaminoethyl)- ⁇ /-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.
  • substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.
  • Some compounds of the formula (I) may have chiral centers and/or geometric isomeric centers (E- and Z-isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess cyclin-dependent kinase (CDK) inhibitory activity.
  • CDK cyclin-dependent kinase
  • the invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess CDK inhibitory activity.
  • the compounds of the present invention can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups and suspensions. It can also be administered parenterally, e.g. intravenously, subcutaneously, intramuscularly, intraperitoneally, and locally (intratumorally) in sterile liquid dosage forms.
  • the active ingredient can also be administered intranasally (nose drops) or by inhalation of drug powder mist.
  • Other dosage forms are potentially possible such as administration transdermally, via patch mechanism or ointment.
  • Formulations suitable for oral administration can comprise of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions.
  • Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, propylene glycol, glycerin, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
  • diluents such as water and alcohols, for example, ethanol, benzyl alcohol, propylene glycol, glycerin, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
  • Capsule forms can be of the ordinary hard-or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch.
  • Tablet forms can include one or more of the following: lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers.
  • Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, and gels containing, in addition to the active ingredient, such carriers as are known in the art.
  • a flavor usually sucrose and acacia or tragacanth
  • pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, and gels containing, in addition to the active ingredient, such carriers as are known in the art.
  • Immediate release tablets/capsules solid oral dosage forms are made by conventional and novel processes. These units are taken orally without water for immediate dissolution and delivery of the medication.
  • the active ingredient is mixed in a liquid containing ingredient such as sugar, gelatin, pectin and sweeteners. These liquids are solidified into solid tablets or caplets by freeze drying and solid state extraction techniques.
  • the drug compounds may be compressed with viscoelastic and thermoelastic sugars and polymers or effervescent components to produce porous matrices intended for immediate release, without the need of water.
  • the compounds of the present invention alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation.
  • aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, and nitrogen. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer.
  • the compounds of the present invention can be administered in the form of nose drops, or metered dose and a nasal or buccal inhaler.
  • the drug is delivered from a nasal solution as a fine mist or from a powder as an aerosol.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers and preservatives.
  • the compound can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol such as poly (ethyleneglycol) 400, glycerol ketals, such as 2,2-dimethyl-1 ,3-dioxolane-4- methanol, ethers, an oil, a fatty acid, a fatty acid ester or glyceride, or any acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulos, or emulsifying agents and other
  • Oils which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isosteric acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
  • Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts
  • suitable detergents include: (a) cationic detergents such as, dimethyldialkylammonium halides, and alkylpyridinium halides, (b) anionic detergents such as, alkyl, aryl, and olefin sulfonates, alkyl, olefin, either, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylene polypropylene copolymers, (d) amphoteric detergents such as, alkyl ⁇ -aminopropionates, and 2-alkylimidazoline quaternary ammonium salts, and (e) mixtures thereof.
  • the parenteral formulations typically contain from about 0.5% to about 25% by weight of the active ingredient in solution. Suitable preservatives and buffers can be used in such formulations. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations ranges from about 5% to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
  • HLB hydrophile-lipophile balance
  • Formulations suitable for topical administration include lozenges comprising the active ingredient in a flavor, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier; as well as creams, emulsions, and gels containing, in addition to the active ingredient, such carriers as are known in the art.
  • formulations suitable for rectal administration may be presented as suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.
  • the pharmaceutically acceptable carriers described herein for example, vehicles, adjuvants, excipients, or diluents, are well-known to those who are skilled in the art.
  • the pharmaceutically acceptable carrier is chemically inert to the active compounds and has no detrimental side effects or toxicity under the conditions of use.
  • the pharmaceutically acceptable carriers can include polymers and polymer matrices.
  • Pharmaceutically acceptable excipients are also well-known to those who are skilled in the art. The choice of excipient will be determined in part by the particular compound, as well as the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of the pharmaceutical composition of the present invention. The following methods and excipients are merely exemplary and are in no way limiting.
  • Suitable carriers and excipients include solvents such as water, alcohol, and propylene glycol, solid absorbants and diluents, surface active agents, suspending agent, tableting binders, lubricants, flavors, and coloring agents.
  • Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field, incorporated by reference.
  • the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use.
  • sterile liquid excipient for example, water
  • Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.
  • the requirements for effective pharmaceutical carriers for injectable compositions are well known to those of ordinary skill in the art. See Pharmaceutics and Pharmacy Practice, J.B.
  • the dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the animal over a reasonable time frame.
  • dosage will depend upon a variety of factors including a condition of the animal, the body weight of the animal, as well as the severity and stage of the cancer.
  • a suitable dose is that which will result in a concentration of the active agent in a patient which is known to effect the desired response.
  • the preferred dosage is the amount which results in maximum inhibition of cancer, without unmanageable side effects.
  • the dosage administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired.
  • the size of the dose also will be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side effects that might accompany the administration of the compound and the desired physiological effect.
  • a daily dosage of active ingredient can be expected to be about 0.001 to 1000 milligrams (mg) per kilogram (kg) of body weight, with the preferred dose being 0.1 to about 30 mg/kg.
  • Dosage forms contain from about 1 mg to about 500 mg of active ingredient per unit.
  • the active ingredient will ordinarily be present in any amount of about 0.5-95% weight based on the total weight of the composition.
  • a 5,6-disubstituted uracil (II) may be converted to a 2,4- dichloro-5,6-disubstituted pyrimidine intermediate of formula (III). This key intermediate is allowed to react with heating up to 120°C, as shown in Reaction
  • Ar aryl or heteroaryl
  • Intermediate (III) may react under a Suzuki-type coupling conditions (a palladium catalyst, and a base such as Na 2 C0 3 ) with a boronic acid of type R 4 B(OH) 2 to give a chloropyrimidine of formula (Vlb).
  • This formula (Vlb) compound may undergo reaction with an amine of type R 1 R 6 NH, as previously described in Reaction Scheme 1, to give the compounds of the invention of formula (If).
  • the compound of formula (IV), as previously described in Reaction Scheme 1 may be allowed to react with a boronic acid of type R 4 B(OH) 2 under the Suzuki-type coupling conditions described above to give the compound of the invention of formula (Ig).
  • Another type of compound of the invention, formula (Ih), is prepared as shown in Reaction Scheme 3.
  • a ketone of formula (VII) (wherein R" is methyl, methoxy, -0-CH 2 -O-, fluoro, CN, or N0 2 ) reacts with DMF- dimethylacetal of formula (VIII) in a refluxing solvent such as toluene to give an enaminone intermediate of formula (IX).
  • a guanidine of formula (XII) is also prepared from an amine of formula (XI) and the reagent of formula (X) by heating the two together in a higher boiling solvent such as toluene/acetic acid mixtures. Reaction of the enaminone (IX) with the guanidine (XII) in a protic solvent such as methanol and a base such as sodium methoxide gives the compound of the invention of formula (Ih).
  • Ketones of formula (VII) that are not commercially available may be conveniently prepared by the method illustrated in Reaction Scheme 4.
  • An aryl or heteroaryl bromide of formula (XIII) may be converted to an aryllithium intermediate by halogen-metal exchange with butyllithium; reaction of the intermediate with an amide such as the compound of formula (XIV) provides the corresponding ketone of formula (XV).
  • Additional compounds of formula (I) may be prepared from other formula (I) compounds by elaboration of functional groups present. Such elaboration includes, but is not limited to, hydrolysis, reduction, oxidation, alkylation, acylation, esterification, amidation and dehydration reactions. Such transformations may in some instances require the use of protecting groups by the methods disclosed in T. W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis (Wiley,
  • Method 1 Eluents were A: 2% acetonitrile in water with 0.02% TFA, and B: 2% water in acetonitrile with 0.02% TFA. Elution conditions consisted of a flow rate of 1.0 mL/min with an initial hold at 10% B for 0.5 min, followed by gradient elution from 10% B to 95% B over 3.5 min, followed by a final hold at 95% B for 0.5 min. Total run time was 6.5 min.
  • Celite ® diatomaceous earth filter agent ® Celite Corp.
  • the enamine was prepared according to the process of Example 22 using ethyl 4-methoxybenzoyl acetate to afford the desired product as an orange oil which was used without further purification; MS (ES) 278.0 (M+H) + .
  • Example 34 Preparation of ⁇ /-r4-(3-chloro-4-fluorophenv ⁇ -5-fluoro-2-pyrimidinvn-6- guinolinamine
  • Step 1 To a solution of 2, 4-dichloro-5-fluoropyrimidine (500 mg, 3.0 mmol) in degassed DME/H 2 0 (9.3 mL/1.8 mL) was added 4-carbobutoxyphenyl boronic acid (244 mg, 1.1 equiv), followed by PdCI 2 (dppf) (49 mg, 0.060 mmol). The reaction was stirred at rt overnight. The mixture was concentrated in vacuo and the residue was purified by flash chromatography (95:5 hexanes/ EtOAc) to afford the desired product which was verified by 1 H NMR and LC-MS and used directly in the next step. Step 2. In a 8 mL vial were placed butyl 4-[5-fluoro-2-(6-quinolinylamino)-
  • the compound was prepared analogously to that described in Example 35, Step 1.
  • the crude product was purified by preparative HPLC (C 18 ODS, 10-90% CH 3 CN/H 2 0, 0.1%TFA) and dried in vacuo at 50 °C to afford the desired product as a white solid (30 mg, 0.078 mmol; 11% yield); mp 155-157 °C; MS (ES) 387.4 (M+H) + .
  • Example 39 Preparation of 1-(1 ,3-benzodioxol-5-yl)-2-fluoroethanone
  • the reaction mixture was diluted with EtOAc (25 mL) and H 2 0 (25 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (3 X 10 mL) and the combined organic layers were washed with brine, dried (Na 2 S0 4 ), and concentrated in vacuo. The crude solid was recrystallized from hot EtOH to afford 387 mg (24%) of the desired product as off-white needles.
  • Step 1 2,4-Dichloro-5-fluoropyrimidine (1 equiv) was allowed to react with 4-acetylphenylboronic acid (1.2 equiv), in the presence of PdCI 2 dppf (0.06 equiv) and sodium carbonate (1.5-2 equiv), in DME and water (4:1 v/v) at rt to 60 °C for 2-6 h.
  • the reaction mixture was evaporated to dryness and the residue was purified by silica gel column chromatography (EtOAc-hexane).
  • Step 2 The intermediate from Step 1 was treated with 6-aminoquinoline (2 equiv) in n-BuOH and 2N HCI (1 :1 v/v) at 120 °C for 2-6 days. The solvents were removed by evaporation. The residue was purified by silica gel column (EtOAc- Hexane or MeOH-CH 2 CI 2 ) to give a pure solid product.
  • LC-MS RT 2.04 min; [M+H] + 359.
  • Step 1 5-Fluoro-2,4-dichloropyrimidine (1 equiv) was allowed to react with phenylboronic acid (1.2 equiv) in the presence of PdCI 2 dppf (0.02 equiv) and sodium bicarbonate (3 equiv), in DME and water (4:1 v/v) at 70 °C overnight. The reaction mixture was evaporated to dryness and the residue was purified by Biotage (15% EtOAc/Hexanes) to give the desired product (80% purity) that was used directly in the next step. Step 2.
  • Step 1 The intermediate obtained in Step 1 was treated with 6- aminoquinoline (2 equiv) in n-BuOH/1N HCI (1/1) at 120 °C, or in 1 N HCI at 100 °C for 10 days. It was cooled and neutralized with 2N Na 2 C0 3 , and extracted with n-BuOH. The organic layer was collected, and dried. The resulting crude product was purified by preparative TLC (60% EtOAc / hexanes). LC-MS: RT 2.08 min;
  • Step 1 To a solution of 2,4-dichloro-5-fluoropyrimidine (500 mg, 3.0 mmol) in degassed DME/H 2 0 (9.3 mL/1.8 mL) was added 3-trifluoromethyl phenylboronic acid (627 mg, 3.3 mmol), followed by PdCI 2 (dppf) (49 mg, 0.060 mmol). The reaction was stirred at rt overnight. The mixture was concentrated under reduced pressure and the residue was purified by flash chromatography (95:5 hexanes/EtOAc) to afford the desired product. The product was verified by 1 H NMR and LC/MS.
  • Step 2 To a solution of 2-chloro-5-fluoro-4-(3-trifluoromethyl phenyl)pyrimidine obtained in Step 1 (100 mg, 0.36 mmol) in n-BuOH (2 mL) were added an 6-amino quinoline (1 equiv) and 1 N HCI (1 mL). The mixture was shaken at 125 °C over 4 days. The mixture was cooled to rt and concentrated under reduced pressure. The crude product was purified by preparative HPLC (C ⁇ ODS, 10-90% CH 3 CN/H 2 0, 0.1%TFA) and dried in vacuo at 45 °C to afford the desired product in 12-17% yield. The product was verified by 1 H NMR and
  • Elk-1 Assay The following assay measures the inhibitory activity of the compounds on
  • Elk-1 transactivated luciferase expression is a gene regulatory protein that is activated by MAP kinases (mitogen activated protein kinases).
  • MAP kinases mitogen activated protein kinases
  • epidermal growth factor (EGF) stimulates Elk-1 transactivation of luciferase expression through phosphorylation of the Gal4 (a yeast gene activator protein)-Elk-1 fusion protein (Hexdall and Zheng, 2001 , Boulikas 1995).
  • EGF epidermal growth factor
  • 1 luc cells are plated at 2 x 10 4 cells per well in 96-well plates in complete medium (DMEM, 10% FBS, 20 mM HEPES, 100 U/mL penicillin, 100 ⁇ g/mL streptomycin, 250 ⁇ g/ml G418 (geneticin) and 100 ⁇ g/ml hygromycin B; all reagents Gibco BRL).
  • DMEM 10% FBS
  • 20 mM HEPES 100 U/mL penicillin
  • 100 ⁇ g/mL streptomycin 250 ⁇ g/ml G418 (geneticin) and 100 ⁇ g/ml hygromycin B; all reagents Gibco BRL
  • the cells are incubated at 37 °C in 5% C0 2 in a humidified incubator overnight.
  • the cells are washed and subsequently incubated in serum-free medium containing 1 % fatty acid free bovine serum albumin (BSA) for an additional 24 hours.
  • BSA bovine serum
  • Test compounds are added in serum-free medium and the plates are incubated for 45 min followed by addition of 100 ng/ml recombinant EGF or 50 ng/ml PMA (phorbol 12-myristate 13-acetate, Sigma). After a 5 h incubation period, luciferase activity is quantified in a Wallace Luminometer.
  • HCT 116 human colorectal carcinoma cells (ATCC CCL247) were cultured in standard growth medium (DMEM, 10% FBS, 10 mM HEPES, 2 mM glutamine,
  • MTS assay e.g. Promega CellTiter 96 Aqueous One Solution Cell Proliferation Assay #G3581. Briefly, the MTS assay is a colorimetric method for determining the number of viable cells in the proliferation assay.
  • the MTS (3- (4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H- tetrazolium) reagent is bioreduced by cells into a colored formazan product that is soluble in tissue cultured medium.
  • the quantity of formazan product as measured by the amount of 490 nm absorbance is directly proportional to the number of living cells in culture.
  • Test compounds were dissolved in 100% DMSO (dimethylsulfoxide) to prepare 10 mM stocks. Stocks were further diluted 1 :250 in growth medium to yield working stocks of 40 ⁇ M test compound in 0.4% DMSO.
  • Test compounds were serially diluted in a 6 point dose response from 10 ⁇ M to 0.033 ⁇ M in growth medium containing 0.4% DMSO to maintain constant DMSO concentrations for all wells.
  • One hundred microliters of diluted test compound were added to each culture well to give a final volume of 200 ⁇ L).
  • the treated cells were incubated for 72h at 37 °C. After the completion of the 72h incubation, 40 ⁇ L of MTS reagent is added to each well. The plates were incubated for 30min at 37°C and read at 490 nm.
  • the IC 50 values were determined with a least squares analysis program using compound concentration versus percent inhibition.
  • % Inhibition [1-(T 72h test-T 0 h)/(T 72 h ctrl-T 0h )] x 100 where
  • T 72h test LDH activity at 72 h in presence of test compound
  • T 7 2h Ctrl LDH activity at 72 h in absence of test compound
  • HCT116 or H460 (ATCC #HTB177) cells are mixed with an agar-medium 1 x DMEM (DMEM powder, Gibco) + 1x FBS at a ratio 3:2; i.e. 3 mL agar (SeaPlaque agarose, FMC Corporation) + 2 mL cells.
  • the initial cell concentration is 5000 cells/mL (resulting in 100 cells/well).
  • 50 ⁇ L is plated as a bottom layer agar mix consisting of 6.3 mL 4x agar, 6.3 mL 2x DMEM, and 12.5 mL 1x DMEM + 2x FBS for a 0.6% f.c.
  • a suitable assay for determining apoptosis is as follows. H460 human lung cancer cells are plated in six well plates (Costar 3506) at 250,000 cells per well in standard medium (DMEM, 10% FBS, 10 mM HEPES, 2 mM glutamine, 100 U/mL penicillin, 100 ⁇ g/mL streptomycin) and incubated over night at 37 °C in 5% C0 2 in a humidified incubator. The cells are treated with various concentrations of the test compounds for 24 h. Cells are harvested and fixed with 1 % paraformaldehyde on ice for 15 min.
  • DMEM 10% FBS
  • 10 mM HEPES 2 mM glutamine
  • penicillin 100 ⁇ g/mL streptomycin
  • the cells are rinsed and put in ice cold ethanol (80%) overnight at -20 °C.
  • Apoptosis is detected using a TUNEL assay (Pharmingen, APO-BRDU kit) as described by the manufacturer. Briefly, cells are incubated with DNA labeling solution for 1 h at 37 °C, washed and subsequently incubated with propidium iodide. In a dark room, the cells are Rnase treated. Samples were analyzed using a FACS Calibur (Becton Dickinson) using CellQuest software. Using this assay, a representative compound of the present invention induced apoptosis.
  • Inhibition of tumor growth in vivo is readily determined via the following assay: HCT 116, H460, or A549 cells are cultured as described above. The cells are harvested by trypsinization, washed, counted, adjusted to 2.5x10 7 cells/mL with ice cold phosphate-buffered saline (PBS), and subsequently stored on ice until transplantation. Xenograft experiments are conducted using eight-to-ten week-old female NCr nude mice (Taconic Labs) with an average body mass of about 20-25g. All the procedures are performed using sterile technique and in accordance with IACUC guidelines.
  • various dosages e.g. 0.75, 1.5, 3, 10, 30, and 100 mg/kg
  • schedules e.g. twice a day (bid) for 14 days, once a day for fourteen consecutive days, or every other day for seven treatments in total.
  • a suitable vehicle for oral administration is Cremophor, ethanol and 0.9% saline (12.5:12.5:75). Tumor measurements are performed twice per week. Tumor weights are calculated as described above. Student's T - test is used to verify the significance of the activity compared to untreated (vehicle only) controls. Animals are sacrificed after treatment and plasma was harvested for pharmacokinetic analyses. Tumors undergo further subsequent analyses, e.g. histology.
  • Example 59 demonstrated antitumor activity in this assay using HCT 116 and H460 cells.
  • Useful pharmaceutical dosage forms for administration of the compounds according to the present invention can be illustrated as follows:
  • a large number of unit hard shell capsules are prepared by filling standard two-piece hard galantine capsules each with 100 mg of powdered active ingredient, 150 mg of lactose, 50 mg of cellulose and 6 mg of magnesium stearate.
  • a mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into molten gelatin to form soft gelatin capsules containing 100 mg of the active ingredient.
  • the capsules are washed and dried.
  • the active ingredient can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a water miscible medicine mix.
  • Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg of active ingredient, 0.2 mg. of colloidal silicon dioxide, 5 mg of magnesium sterate, 275 mg of microcrystalline cellulose, 11 mg. of starch, and 98.8 mg of lactose. Appropriate aqueous and non-aqueous coatings may be applied to increase palatability, improve elegance and stability or delay absorption.
  • the active ingredient is mixed in a liquid containing ingredient such as sugar, gelatin, pectin and sweeteners. These liquids are solidified into solid tablets or caplets by freeze drying and solid state extraction techniques.
  • the drug compounds may be compressed with viscoelastic and thermoelastic sugars and polymers or effervescent components to produce porous matrices intended ' for immediate release, without the need of water.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé représenté par la formule dans laquelle chaque X est indépendamment NR1R6, NR4R5, ou R4, à condition qu'un X au moins soit NR1R6; chaque R1est indépendamment un noyau bicyclique fondu non saturé éventuellement substitué contenant 9 ou 10 atomes contenant éventuellement de 1 à 4 hétéroatomes sélectionnés dans le groupe comprenant N, S et O; et les variables R2-6 sont telles que définies dans la première revendication. Ces composés sont des inhibiteurs de kinases utilisés dans le traitement du cancer et des infections virales.
PCT/US2002/030616 2001-09-25 2002-09-25 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer WO2003030909A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32427601P 2001-09-25 2001-09-25
US60/324,276 2001-09-25
US35250902P 2002-01-31 2002-01-31
US60/352,509 2002-01-31

Publications (1)

Publication Number Publication Date
WO2003030909A1 true WO2003030909A1 (fr) 2003-04-17

Family

ID=26984370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/030616 WO2003030909A1 (fr) 2001-09-25 2002-09-25 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2003030909A1 (fr)

Cited By (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041810A1 (fr) * 2002-11-05 2004-05-21 Vertex Pharmaceuticals Incorporated Composes utiles comme inhibiteurs de proteines jak et autres proteines kinase
WO2004048365A1 (fr) * 2002-11-21 2004-06-10 Chiron Corporation Pyrimidines 2,4,6-trisubstitutees utilisees comme inhibiteurs de phosphotidylinositol (pi) 3-kinase et leur utilisation dans le traitement du cancer
WO2004080979A1 (fr) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Nouveaux derives de 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl cetone
WO2004080980A1 (fr) * 2003-03-14 2004-09-23 Novartis Ag 2,4-di(phenylamino)pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
WO2004056786A3 (fr) * 2002-12-20 2004-10-21 Pfizer Prod Inc Composes pour traiter le developpement anormal de cellules
WO2004074244A3 (fr) * 2003-02-20 2004-11-11 Smithkline Beecham Corp Composes de pyrimidine
WO2004098607A1 (fr) * 2003-05-08 2004-11-18 Applied Research Systems Ars Holding N. V. Acétonitriles de pyridinyle
WO2005016894A1 (fr) * 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidine diamines utiles dans le cadre du traitement de maladies neoplasiques, de troubles inflammatoires et de troubles du systeme immunitaire
WO2005023780A1 (fr) * 2003-09-05 2005-03-17 Pfizer Products Inc. Synthèse sélective de pyrimidines substituées en cf3
WO2005026158A1 (fr) * 2003-09-16 2005-03-24 Novartis Ag Derives de 2,4-di(hetero)-arylamino-pyrimidine comme inhibiteurs des kinases zap-70 et/ou syk
WO2005026130A1 (fr) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines utiles dans le traitement de troubles proliferatifs
WO2005016893A3 (fr) * 2003-07-30 2005-06-09 Rigel Pharmaceuticals Inc Methodes de traitement ou de prevention de maladies auto-immunes a l'aide de composes de 2,4-pyrimidinediamine
WO2005013996A3 (fr) * 2003-08-07 2005-06-09 Rigel Pharmaceuticals Inc Composes de 2,4-pyrimidinediamine et leurs utilisations comme agents antiproliferants
WO2005103036A1 (fr) * 2004-04-23 2005-11-03 Biofocus Discovery Ltd Pyrimidine-4-yl-1h-indazol-5yl-amines utiles comme inhibiteurs des chk1 kinases
WO2005111016A1 (fr) * 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
WO2005111024A1 (fr) * 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine destines au traitement de croissance cellulaire anormale
WO2005111023A1 (fr) * 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine pour le traitement de la croissance cellulaire anormale
WO2006004776A1 (fr) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. Composés de 4-pyrimidineamine et leurs utilisations en tant qu’agent anti-prolifération
WO2005118544A3 (fr) * 2004-05-18 2006-02-16 Rigel Pharmaceuticals Inc Composes pyrimidinediamines a substitution cycloalkyle et leurs utilisations
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109335B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2006117560A1 (fr) * 2005-05-05 2006-11-09 Astrazeneca Ab Pyrimidines substituées par des groupements pyrazolyl-amino et leur application au traitement de cancers
US7145008B2 (en) 2004-05-14 2006-12-05 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2007009681A1 (fr) * 2005-07-15 2007-01-25 Glaxo Group Limited Derives de la 1, 1-dioxid0-2, 3-dihydro-l, 2-benzisothiaz0l-6-yl-1h-indazol-4-yl-2, 4-pyrimidine diamine
US7172633B2 (en) 2003-06-16 2007-02-06 L'ORéAL S.A. Lightening dye composition comprising at least one cationic direct dye containing mixed chromophores
WO2007028445A1 (fr) * 2005-07-15 2007-03-15 Glaxo Group Limited Composés 6-indolyl-4-ylamino-5-halogéno-2-pyrimidinylamino
US7201779B2 (en) 2003-06-16 2007-04-10 L'oreal S.A. Dye composition comprising at least one direct dye containing mixed chromophores
FR2893941A1 (fr) * 2005-11-25 2007-06-01 Sanofi Aventis Sa Nouveaux derives de 2,4-dianilinopyridines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
US7235561B2 (en) 2001-05-29 2007-06-26 Schering Ag Compound and a composition including such a compound
WO2007098507A2 (fr) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions et méthodes destinées à l'inhibition de la voie jak
US7288121B2 (en) 2004-02-27 2007-10-30 L'oreal S.A. Composition comprising at least one mixed dye comprising at least one chromophore chosen from compounds of the methine family and/or the carbonyl family, dyeing process and kit, and mixed dyes
US7300471B2 (en) 2004-02-27 2007-11-27 L'oreal S.A. Composition comprising at least one mixed dye based on at least one chromophore of azo or tri(hetero) arylmethane type, dyeing process and mixed dyes.
US7303591B2 (en) 2004-02-27 2007-12-04 L'oreal S.A. Composition comprising at least one mixed dye comprising at least two chromophores of (hetero) aromatic nitro or cyclic azine type, dyeing process, and mixed dyes
US7304071B2 (en) 2002-08-14 2007-12-04 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US7312227B2 (en) 2002-11-01 2007-12-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
US7329671B2 (en) 2002-02-01 2008-02-12 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
JP2008510763A (ja) * 2004-08-27 2008-04-10 ノバルティス アクチエンゲゼルシャフト ピリミジン誘導体
WO2006055561A3 (fr) * 2004-11-15 2008-05-22 Rigel Pharmaceuticals Inc Composes de 3-aminocarbonyl bicycloheptene pyrimidinediamine stereo-isomeriquement enrichis et leurs utilisations
WO2008111441A1 (fr) 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. Composition pharmaceutique
WO2008129380A1 (fr) 2007-04-18 2008-10-30 Pfizer Products Inc. Dérivés de sulfonyle amide pour le traitement d'une croissance cellulaire anormale
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US7504403B2 (en) 2004-01-22 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
JP2009525337A (ja) * 2006-01-30 2009-07-09 エクセリクシス， インク． Ｊａｋ−２調節因子としての４−アリール−２−アミノ−ピリミジン類又は４−アリール−２−アミノアルキル−ピリミジン類と使用方法
US7582122B2 (en) 2005-08-26 2009-09-01 L'oreal S.A. Mixed cationic dyes comprising at least one anthraquinone chromophore and their use in methods of hair dyeing
WO2009136995A2 (fr) 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibiteurs de la syk protéine kinase
JP2009542604A (ja) * 2006-07-06 2009-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
US7666901B2 (en) 2004-10-13 2010-02-23 Wyeth Analogs of 17-hydroxywortmannin as PI3K inhibitors
EP2161259A1 (fr) 2008-09-03 2010-03-10 Bayer CropScience AG 4-haloalkyle-diaminopyrimidines substitués
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2010072155A1 (fr) * 2008-12-26 2010-07-01 复旦大学 Dérivé de pyrimidine, sa méthode de synthèse et ses applications
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
JP2010524952A (ja) * 2007-04-16 2010-07-22 ハッチソン メディファーマ エンタープライジズ リミテッド ピリミジン誘導体
US7767680B2 (en) 2004-11-03 2010-08-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7820654B2 (en) 2004-09-23 2010-10-26 Dr. Reddy's Laboratories Ltd. Pyrimidine compounds, process for their preparation and compositions containing them
US7820648B2 (en) 2005-12-21 2010-10-26 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US20100305099A1 (en) * 2007-12-03 2010-12-02 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
WO2010138578A1 (fr) * 2009-05-27 2010-12-02 Abbott Laboratories Inhibiteurs pyrimidines de l'activité kinase
WO2010136559A1 (fr) * 2009-05-29 2010-12-02 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidines pour le traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale
WO2011018517A1 (fr) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Préparation régiosélective de dérivés de 2-amino-5-trifluorométhylpyrimidine
WO2011018518A1 (fr) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Préparation régiosélective de dérivés de 2-amino-5trifluorométhylpyrimidine
US20110046108A1 (en) * 2006-01-26 2011-02-24 Astrazeneca Ab Pyrimidine derivatives
US7943627B2 (en) 2002-03-15 2011-05-17 Novartis Ag 2,4-diaminopyrimidine derivatives
US8013154B2 (en) 2007-10-09 2011-09-06 Niyaz Noormohamed M Insecticidal substituted azinyl derivatives
US8039479B2 (en) 2006-12-08 2011-10-18 Irm Llc Compounds and compositions as protein kinase inhibitors
US8058279B2 (en) 2007-10-09 2011-11-15 Dow Agrosciences Llc Insecticidal pyrimidinyl aryl hyrdrazones
WO2011144742A1 (fr) 2010-05-21 2011-11-24 Chemilia Ab Nouveaux dérivés de pyrimidine
US8067588B2 (en) 2007-10-09 2011-11-29 Dow Agrosciences Llc Insecticidal (1,3,5)-triazinyl phenyl hydrazones
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
US8173808B2 (en) 2009-12-30 2012-05-08 Arqule, Inc. Substituted naphthalenyl-pyrimidine compounds
US8173647B2 (en) 2007-02-06 2012-05-08 Gordana Atallah PI 3-kinase inhibitors and methods of their use
WO2012061415A1 (fr) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Oxypyrimidines en tant que modulateurs de syk
WO2012061418A2 (fr) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Benzamides et nicotinamides en tant que modulateurs de syk
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US8217035B2 (en) 2006-01-20 2012-07-10 Novartis Ag Pyrimidine derivatives used as PI-3-kinase inhibitors
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2012101013A1 (fr) 2011-01-28 2012-08-02 Boehringer Ingelheim International Gmbh Pyridinyl-pyrimidines substituées et leur utilisation en tant que médicaments
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8273744B2 (en) 2008-02-04 2012-09-25 Mercury Therapeutics, Inc. AMPK modulators
EP2502924A1 (fr) 2011-03-24 2012-09-26 Chemilia AB Nouveaux dérivés de pyrimidine
WO2012127032A1 (fr) 2011-03-24 2012-09-27 Chemilia Ab Nouveaux dérivés de pyrimidine
US8309566B2 (en) 2008-02-15 2012-11-13 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US8354420B2 (en) 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
US8377943B2 (en) 2008-11-14 2013-02-19 Boehringer Ingelheim International Gmbh 2,4-diaminopyrimidine derivates as PTK2-inhibitors for the treatment of abnormal cell growth
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
JP2013112658A (ja) * 2011-11-30 2013-06-10 Toray Ind Inc Ｎ−（ヨードフェニル）ピリミジニルアミン誘導体の製造方法
CN101765591B (zh) * 2007-07-26 2013-11-27 诺华股份有限公司 用于治疗炎性或过敏性病症的嘧啶衍生物
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP2130541A3 (fr) * 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Procédés de traitement ou de prévention des maladies auto-immunes avec des composants de pyrimidinediamine 2,4
EP2711365A1 (fr) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer
EP2711364A1 (fr) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl ou benzimidazolyl)amino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer
US8697715B2 (en) 2012-03-01 2014-04-15 Array Biopharma, Inc. Serine/threonine kinase inhibitors
US8785630B2 (en) 2010-07-20 2014-07-22 Vestaron Corporation Insecticidal triazines and pyrimidines
WO2014126954A1 (fr) * 2013-02-13 2014-08-21 OSI Pharmaceuticals, LLC Synthèse régiosélective de pyrimidines substituées
US8815882B2 (en) 2010-11-10 2014-08-26 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
US8865894B2 (en) 2012-02-24 2014-10-21 Novartis Ag Oxazolidin-2-one compounds and uses thereof
US8952027B2 (en) 2008-04-16 2015-02-10 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8957068B2 (en) 2011-09-27 2015-02-17 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US9000007B2 (en) 2011-09-27 2015-04-07 Dr. Reddy's Laboratories Ltd. 5-benzylaminomethyl-6-aminopyrazolo [3, 4 -B] pyridine derivatives as cholesteryl ester-transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
CN104529904A (zh) * 2015-01-09 2015-04-22 苏州明锐医药科技有限公司 玻玛西尼的制备方法
US9040558B2 (en) 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9096624B2 (en) 2009-06-01 2015-08-04 OSI Pharmaceuticals, LLC Amino pyrimidine anticancer compounds
US9102625B2 (en) 2010-11-01 2015-08-11 Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
CN104910049A (zh) * 2015-06-16 2015-09-16 苏州明锐医药科技有限公司 Azd9291中间体及其制备方法
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
CN105130907A (zh) * 2015-07-29 2015-12-09 沈阳药科大学 嘧啶类化合物及其用途
US9212181B2 (en) 2008-06-27 2015-12-15 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US9359308B2 (en) 2011-11-23 2016-06-07 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US9388171B2 (en) 2012-08-27 2016-07-12 Genetech, Inc. Serine/threonine kinase inhibitors
US9394281B2 (en) 2014-03-28 2016-07-19 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US9409887B2 (en) 2010-11-10 2016-08-09 Celgene Avilomics Research, Inc. Mutant-selective EGFR inhibitors and uses thereof
US9409921B2 (en) 2008-06-27 2016-08-09 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines as kinase inhibitors
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9434719B2 (en) 2013-03-14 2016-09-06 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN106188038A (zh) * 2015-06-01 2016-12-07 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
US9593082B2 (en) 2005-06-08 2017-03-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9604936B2 (en) 2010-08-10 2017-03-28 Celgene Car Llc Besylate salt of a BTK inhibitor
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
WO2017114510A1 (fr) * 2015-12-31 2017-07-06 中国科学院上海药物研究所 Composé présentant une activité inhibitrice de l'erk kinase, son procédé de préparation et utilisation associée
WO2017125530A1 (fr) * 2016-01-22 2017-07-27 Janssen Pharmaceutica Nv Nouveaux dérivés de cyanoindoline utilisés comme inhibiteurs de nik
WO2017125534A1 (fr) * 2016-01-22 2017-07-27 Janssen Pharmaceutica Nv Nouveaux dérivés de cyanoindoline à substitution hétéroaromatique à 6 chaînons utilisés comme inhibiteurs de nik
CN107151233A (zh) * 2016-03-03 2017-09-12 沈阳药科大学 含腙的嘧啶类衍生物及其用途
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9834571B2 (en) 2012-05-05 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2017211268A1 (fr) * 2016-06-07 2017-12-14 上海宣创生物科技有限公司 Forme cristalline a, forme cristalline b et forme cristalline c de bemaciclib et procédé de préparation correspondant
WO2018002217A1 (fr) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Dérivés hétéroaromatiques en tant qu'inhibiteurs de nik
WO2018002219A1 (fr) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Nouveaux dérivés de cyanoindoline comme inhibiteurs de nik
CN107652273A (zh) * 2016-07-26 2018-02-02 沈阳药科大学 嘧啶类衍生物及其制备方法和应用
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
CN107868082A (zh) * 2016-09-22 2018-04-03 上海宣创生物科技有限公司 玻玛西尼甲磺酸盐a晶型及其制备方法
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10059689B2 (en) 2014-10-14 2018-08-28 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN108503623A (zh) * 2018-05-11 2018-09-07 四川大学 一种抑制prmt7的化合物及其制备方法与应用
US20180339979A1 (en) * 2015-04-01 2018-11-29 Rigel Pharmaceuticals, Inc. TGF-ß Inhibitors
WO2019008011A1 (fr) 2017-07-06 2019-01-10 Janssen Pharmaceutica Nv Nouveaux dérivés d'azaindoline substitués utilisés en tant qu'inhibiteurs de nik
US20190023666A1 (en) * 2017-07-18 2019-01-24 GiraFpharma LLC Heterocyclic compounds as adenosine antagonists
US10323023B2 (en) 2017-06-30 2019-06-18 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
US10391094B2 (en) 2010-11-07 2019-08-27 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis
WO2019200502A1 (fr) * 2018-04-16 2019-10-24 杭州领业医药科技有限公司 Forme cristalline de mésylate d'abémaciclib, procédé de préparation et composition pharmaceutique associés
CN110669038A (zh) * 2019-09-21 2020-01-10 温州医科大学 一种嘧啶类fgfr4v550l抑制剂及其制备方法和应用
CN110746402A (zh) * 2019-09-21 2020-02-04 温州医科大学 一种2-n-芳基-4-n-芳基-5-氟嘧啶类化合物及其制备方法和应用
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN111423419A (zh) * 2020-01-17 2020-07-17 温州医科大学 一种小分子化合物cyy-260及其在制备抗肿瘤药物中的应用
CN111484484A (zh) * 2020-04-13 2020-08-04 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
US10793561B2 (en) 2017-07-18 2020-10-06 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
EA037358B1 (ru) * 2016-03-10 2021-03-17 Янссен Фармасьютика Нв Новые замещённые производные цианиндолина в качестве nik-ингибиторов
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
US11306071B2 (en) 2019-01-18 2022-04-19 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11390609B2 (en) 2017-06-30 2022-07-19 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11518758B2 (en) 2019-05-10 2022-12-06 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
US11530206B2 (en) 2019-05-10 2022-12-20 Deciphera Pharmaceuticals, Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
US11590134B2 (en) 2019-06-17 2023-02-28 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2024182751A1 (fr) * 2023-03-02 2024-09-06 Sionna Therapeutics Inc. Modulateurs de nbd1 et leurs procédés d'utilisation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019065A1 (fr) * 1995-11-20 1997-05-29 Celltech Therapeutics Limited 2-anilinopyrimidines substituees utiles en tant qu'inhibiteurs de proteine kinase
WO1998011095A1 (fr) * 1996-09-16 1998-03-19 Celltech Therapeutics Limited Pyrimidineamines 2-substituees, leur preparation et leur utilisation comme inhibiteurs de proteine kinase
WO2000018761A1 (fr) * 1998-09-29 2000-04-06 American Cyanamid Company Inhibiteurs de proteines de type tyrosine kinases a base de 3-cyanoquinolines substituees
WO2001040215A1 (fr) * 1999-11-30 2001-06-07 Pfizer Products Inc. Composes de 2,4-diaminopyrimidine utilises comme immunodepresseurs
WO2001064654A1 (fr) * 2000-03-01 2001-09-07 Astrazeneca Ab Composes de pyrimidine
WO2002022601A1 (fr) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes pyrazoliques utiles comme inhibiteurs de la proteine kinase

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019065A1 (fr) * 1995-11-20 1997-05-29 Celltech Therapeutics Limited 2-anilinopyrimidines substituees utiles en tant qu'inhibiteurs de proteine kinase
WO1998011095A1 (fr) * 1996-09-16 1998-03-19 Celltech Therapeutics Limited Pyrimidineamines 2-substituees, leur preparation et leur utilisation comme inhibiteurs de proteine kinase
WO2000018761A1 (fr) * 1998-09-29 2000-04-06 American Cyanamid Company Inhibiteurs de proteines de type tyrosine kinases a base de 3-cyanoquinolines substituees
WO2001040215A1 (fr) * 1999-11-30 2001-06-07 Pfizer Products Inc. Composes de 2,4-diaminopyrimidine utilises comme immunodepresseurs
WO2001064654A1 (fr) * 2000-03-01 2001-09-07 Astrazeneca Ab Composes de pyrimidine
WO2002022601A1 (fr) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes pyrazoliques utiles comme inhibiteurs de la proteine kinase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WERBEL ET AL.: "Synthesis and antimalarial effects of 5,6-dichloro-2-[(4-[[4-(diethylamino)-1-methylbutyl]amino]-6-methyl-2-pyrimidinyl)amino]benzimidazole and related benzimidazoles and 1H-imidazo[4,5-b]pyridines (1,2)", J. HETEROCYCL. CHEM., vol. 10, no. 3, 1973, pages 363-382, XP009001685 *

Cited By (404)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235561B2 (en) 2001-05-29 2007-06-26 Schering Ag Compound and a composition including such a compound
US7589200B2 (en) * 2002-02-01 2009-09-15 Rigel Pharmaceuticals, Inc. 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds
US7642351B2 (en) * 2002-02-01 2010-01-05 Rogel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7329671B2 (en) 2002-02-01 2008-02-12 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10709703B2 (en) 2002-02-01 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7803939B2 (en) 2002-02-01 2010-09-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7332484B2 (en) 2002-02-01 2008-02-19 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8334296B2 (en) 2002-02-01 2012-12-18 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10682350B2 (en) 2002-02-01 2020-06-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7329672B2 (en) 2002-02-01 2008-02-12 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7820819B2 (en) 2002-02-01 2010-10-26 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7655797B2 (en) 2002-02-01 2010-02-02 Rigel Pharmaceuticals, Inc. Intermediates for making 2,4-pyrimidinediamine compounds
US7557210B2 (en) * 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7550460B2 (en) 2002-02-01 2009-06-23 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7435814B2 (en) 2002-02-01 2008-10-14 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds and their uses
US7485724B2 (en) * 2002-02-01 2009-02-03 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7498435B2 (en) 2002-02-01 2009-03-03 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8431589B2 (en) 2002-03-15 2013-04-30 Novartis Ag 2,4-diaminopyrimidine derivatives
US7943627B2 (en) 2002-03-15 2011-05-17 Novartis Ag 2,4-diaminopyrimidine derivatives
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
EP2130541A3 (fr) * 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Procédés de traitement ou de prévention des maladies auto-immunes avec des composants de pyrimidinediamine 2,4
US7825116B2 (en) 2002-07-29 2010-11-02 Rigel Pharmaceuticals, Inc. N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines
US7812029B1 (en) 2002-07-29 2010-10-12 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7304071B2 (en) 2002-08-14 2007-12-04 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US7312227B2 (en) 2002-11-01 2007-12-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
WO2004041810A1 (fr) * 2002-11-05 2004-05-21 Vertex Pharmaceuticals Incorporated Composes utiles comme inhibiteurs de proteines jak et autres proteines kinase
US7348335B2 (en) 2002-11-05 2008-03-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
WO2004048365A1 (fr) * 2002-11-21 2004-06-10 Chiron Corporation Pyrimidines 2,4,6-trisubstitutees utilisees comme inhibiteurs de phosphotidylinositol (pi) 3-kinase et leur utilisation dans le traitement du cancer
EP2316831A1 (fr) * 2002-11-21 2011-05-04 Novartis AG Dérivés de pyrimidine 2,4,6-trisubstituée comme inhibiteurs de Phosphotidylinositol (PI) 3-kinase pour le traitement de cancers.
US7423148B2 (en) 2002-11-21 2008-09-09 Chiron Corporation Small molecule PI 3-kinase inhibitors and methods of their use
US7767669B2 (en) 2002-11-21 2010-08-03 Novartis Ag Small molecule PI 3-kinase inhibitors and methods of their use
EA013811B1 (ru) * 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
US7351712B2 (en) 2002-12-20 2008-04-01 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7674796B2 (en) 2002-12-20 2010-03-09 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004056786A3 (fr) * 2002-12-20 2004-10-21 Pfizer Prod Inc Composes pour traiter le developpement anormal de cellules
NL1025071C2 (nl) * 2002-12-20 2004-12-30 Pfizer Prod Inc Verbindingen voor de behandeling van abnormale celgroei.
US7741336B2 (en) 2002-12-20 2010-06-22 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109335B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7514446B2 (en) 2003-02-20 2009-04-07 Smithkline Beecham Corporation Pyrimidine compounds
WO2004074244A3 (fr) * 2003-02-20 2004-11-11 Smithkline Beecham Corp Composes de pyrimidine
WO2004080979A1 (fr) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Nouveaux derives de 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl cetone
EP2275413A1 (fr) * 2003-03-14 2011-01-19 Novartis AG Composés de 2,4-di(phenylamino)pyrimidine er leur utilisation dans le traitement de maladies néoplastiques, inflammatoires et du système immunitaire
US7964592B2 (en) 2003-03-14 2011-06-21 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US8263590B2 (en) 2003-03-14 2012-09-11 Carlos Garcia-Echeverria Pyrimidine derivatives
WO2004080980A1 (fr) * 2003-03-14 2004-09-23 Novartis Ag 2,4-di(phenylamino)pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
JP4885709B2 (ja) * 2003-05-08 2012-02-29 メルク セローノ ソシエテ アノニム ピリジニルアセトニトリル類
JP2006525281A (ja) * 2003-05-08 2006-11-09 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ピリジニルアセトニトリル類
AU2004237412B2 (en) * 2003-05-08 2010-03-11 Merck Serono Sa Pyridinyl acetonitriles
WO2004098607A1 (fr) * 2003-05-08 2004-11-18 Applied Research Systems Ars Holding N. V. Acétonitriles de pyridinyle
US7855212B2 (en) 2003-05-08 2010-12-21 Merck Serono Sa Pyridinyl acetonitriles
US7172633B2 (en) 2003-06-16 2007-02-06 L'ORéAL S.A. Lightening dye composition comprising at least one cationic direct dye containing mixed chromophores
US7201779B2 (en) 2003-06-16 2007-04-10 L'oreal S.A. Dye composition comprising at least one direct dye containing mixed chromophores
US7560466B2 (en) 2003-07-30 2009-07-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US9751893B2 (en) 2003-07-30 2017-09-05 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7452879B2 (en) 2003-07-30 2008-11-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7582648B2 (en) 2003-07-30 2009-09-01 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
WO2005016893A3 (fr) * 2003-07-30 2005-06-09 Rigel Pharmaceuticals Inc Methodes de traitement ou de prevention de maladies auto-immunes a l'aide de composes de 2,4-pyrimidinediamine
US8809341B2 (en) 2003-08-07 2014-08-19 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
JP2007501793A (ja) * 2003-08-07 2007-02-01 リゲル ファーマシューティカルズ，インコーポレイティド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
US9598432B2 (en) 2003-08-07 2017-03-21 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
WO2005013996A3 (fr) * 2003-08-07 2005-06-09 Rigel Pharmaceuticals Inc Composes de 2,4-pyrimidinediamine et leurs utilisations comme agents antiproliferants
US7884111B2 (en) 2003-08-07 2011-02-08 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
JP2007502260A (ja) * 2003-08-15 2007-02-08 ノバルティス　アクチエンゲゼルシャフト 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
WO2005016894A1 (fr) * 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidine diamines utiles dans le cadre du traitement de maladies neoplasiques, de troubles inflammatoires et de troubles du systeme immunitaire
KR100904570B1 (ko) * 2003-08-15 2009-06-25 노파르티스 아게 종양성 질환, 염증성 및 면역계 장애의 치료에 유용한2,4-피리미딘디아민
US7893074B2 (en) 2003-08-15 2011-02-22 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US7122670B2 (en) 2003-09-05 2006-10-17 Pfizer Inc Selective synthesis of CF3-substituted pyrimidines
JP2007504211A (ja) * 2003-09-05 2007-03-01 ファイザー・プロダクツ・インク Ｃｆ３−置換ピリミジンの選択的合成
KR100694732B1 (ko) * 2003-09-05 2007-03-14 화이자 프로덕츠 인크. Ｃｆ3-치환 피리미딘의 선택적 합성
WO2005023780A1 (fr) * 2003-09-05 2005-03-17 Pfizer Products Inc. Synthèse sélective de pyrimidines substituées en cf3
JP4842816B2 (ja) * 2003-09-05 2011-12-21 ファイザー・プロダクツ・インク Ｃｆ３−置換ピリミジンの選択的合成
CN100465164C (zh) * 2003-09-05 2009-03-04 辉瑞产品公司 Cf3－取代嘧啶的选择性合成
US7671063B2 (en) 2003-09-16 2010-03-02 Novartis Ag 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors
EP2266977A1 (fr) * 2003-09-16 2010-12-29 Novartis AG Composés de 2,4-di[(hétéro)arylamino]pyrimidine comme inhibiteurs de la zap-70 et/ou syk kinase
AU2004272283B9 (en) * 2003-09-16 2008-10-23 Novartis Ag 2,4 di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or Syk inhibitors
AU2004272283B2 (en) * 2003-09-16 2008-10-02 Novartis Ag 2,4 di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or Syk inhibitors
WO2005026158A1 (fr) * 2003-09-16 2005-03-24 Novartis Ag Derives de 2,4-di(hetero)-arylamino-pyrimidine comme inhibiteurs des kinases zap-70 et/ou syk
US8283356B2 (en) 2003-09-16 2012-10-09 Novartis Ag 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors
WO2005026130A1 (fr) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines utiles dans le traitement de troubles proliferatifs
JP2007505858A (ja) * 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
US7504403B2 (en) 2004-01-22 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7288121B2 (en) 2004-02-27 2007-10-30 L'oreal S.A. Composition comprising at least one mixed dye comprising at least one chromophore chosen from compounds of the methine family and/or the carbonyl family, dyeing process and kit, and mixed dyes
US7303591B2 (en) 2004-02-27 2007-12-04 L'oreal S.A. Composition comprising at least one mixed dye comprising at least two chromophores of (hetero) aromatic nitro or cyclic azine type, dyeing process, and mixed dyes
US7300471B2 (en) 2004-02-27 2007-11-27 L'oreal S.A. Composition comprising at least one mixed dye based on at least one chromophore of azo or tri(hetero) arylmethane type, dyeing process and mixed dyes.
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
WO2005103036A1 (fr) * 2004-04-23 2005-11-03 Biofocus Discovery Ltd Pyrimidine-4-yl-1h-indazol-5yl-amines utiles comme inhibiteurs des chk1 kinases
AP2241A (en) * 2004-05-14 2011-06-01 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.
US7145008B2 (en) 2004-05-14 2006-12-05 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CN102127058A (zh) * 2004-05-14 2011-07-20 辉瑞产品有限公司 治疗异常细胞生长的嘧啶衍生物
US7208499B2 (en) 2004-05-14 2007-04-24 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111023A1 (fr) * 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine pour le traitement de la croissance cellulaire anormale
WO2005111024A1 (fr) * 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine destines au traitement de croissance cellulaire anormale
KR100886990B1 (ko) 2004-05-14 2009-03-04 화이자 프로덕츠 인크. 비정상적인 세포성장의 치료를 위한 피리미딘 유도체
WO2005111016A1 (fr) * 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
US7235562B2 (en) 2004-05-14 2007-06-26 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005118544A3 (fr) * 2004-05-18 2006-02-16 Rigel Pharmaceuticals Inc Composes pyrimidinediamines a substitution cycloalkyle et leurs utilisations
US7858633B2 (en) 2004-05-18 2010-12-28 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US8410093B2 (en) 2004-05-18 2013-04-02 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US7868013B2 (en) 2004-05-18 2011-01-11 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US9725419B2 (en) 2004-05-18 2017-08-08 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US8546398B2 (en) 2004-05-18 2013-10-01 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US7482351B2 (en) 2004-06-29 2009-01-27 Rigel Pharmaceuticals, Inc. 4-pyrimidineamine compounds and their uses as anti-proliferative agents
WO2006004776A1 (fr) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. Composés de 4-pyrimidineamine et leurs utilisations en tant qu’agent anti-prolifération
JP2008510763A (ja) * 2004-08-27 2008-04-10 ノバルティス アクチエンゲゼルシャフト ピリミジン誘導体
US7820654B2 (en) 2004-09-23 2010-10-26 Dr. Reddy's Laboratories Ltd. Pyrimidine compounds, process for their preparation and compositions containing them
US7666901B2 (en) 2004-10-13 2010-02-23 Wyeth Analogs of 17-hydroxywortmannin as PI3K inhibitors
US7767680B2 (en) 2004-11-03 2010-08-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US8546414B2 (en) 2004-11-03 2013-10-01 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US8236815B2 (en) 2004-11-03 2012-08-07 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of uses
RU2416604C2 (ru) * 2004-11-15 2011-04-20 Райджел Фармасьютикалз, Инк. Стереоизомерно обогащенные 3-аминокарбонильные бициклогептеновые пиримидиндиамины и их применения
WO2006055561A3 (fr) * 2004-11-15 2008-05-22 Rigel Pharmaceuticals Inc Composes de 3-aminocarbonyl bicycloheptene pyrimidinediamine stereo-isomeriquement enrichis et leurs utilisations
US8101627B2 (en) 2004-11-15 2012-01-24 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
AU2005307849B2 (en) * 2004-11-15 2012-11-15 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US8044054B2 (en) 2004-11-15 2011-10-25 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
CN101171012B (zh) * 2004-11-15 2013-04-17 里格尔药品股份有限公司 富含立体异构体的3-氨基羰基双环庚烯嘧啶二胺化合物及其用途
US8030483B2 (en) 2004-11-15 2011-10-04 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US7863286B2 (en) 2004-11-15 2011-01-04 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US7851480B2 (en) 2004-11-24 2010-12-14 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US9782407B2 (en) 2004-12-31 2017-10-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US9040558B2 (en) 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US9725450B2 (en) 2005-01-13 2017-08-08 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US8101588B2 (en) 2005-01-13 2012-01-24 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US8440661B2 (en) 2005-01-13 2013-05-14 Signal Pharmaceuticals, Llc Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US9187479B2 (en) 2005-01-13 2015-11-17 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US10577381B2 (en) 2005-01-19 2020-03-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9532998B2 (en) 2005-01-19 2017-01-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7563892B1 (en) 2005-01-19 2009-07-21 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4 pyrimidinediamine compounds and their uses
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7538108B2 (en) 2005-01-19 2009-05-26 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8481521B2 (en) 2005-04-18 2013-07-09 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2006117560A1 (fr) * 2005-05-05 2006-11-09 Astrazeneca Ab Pyrimidines substituées par des groupements pyrazolyl-amino et leur application au traitement de cancers
US9222933B2 (en) 2005-05-23 2015-12-29 HMI Medical Innovations, LLC Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US11714080B2 (en) 2005-05-23 2023-08-01 HMI Medical Innovations, LLC Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
US10473643B2 (en) 2005-05-23 2019-11-12 HMI Medical Innovations, LLC Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
US10018619B2 (en) 2005-05-23 2018-07-10 HMI Medical Innovations, LLC Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US11692998B2 (en) 2005-05-23 2023-07-04 HMI Medical Innovations, LLC Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US9645137B2 (en) 2005-05-23 2017-05-09 HMI Medical Innovations, LLC Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US10955408B2 (en) 2005-05-23 2021-03-23 HMI Medical Innovations, LLC Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
US11827628B2 (en) 2005-06-08 2023-11-28 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8399472B2 (en) 2005-06-08 2013-03-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US11198689B2 (en) 2005-06-08 2021-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9593082B2 (en) 2005-06-08 2017-03-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US10421752B2 (en) 2005-06-08 2019-09-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8415365B2 (en) 2005-06-08 2013-04-09 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9248190B2 (en) 2005-06-08 2016-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9732073B2 (en) 2005-06-08 2017-08-15 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2007028445A1 (fr) * 2005-07-15 2007-03-15 Glaxo Group Limited Composés 6-indolyl-4-ylamino-5-halogéno-2-pyrimidinylamino
WO2007009681A1 (fr) * 2005-07-15 2007-01-25 Glaxo Group Limited Derives de la 1, 1-dioxid0-2, 3-dihydro-l, 2-benzisothiaz0l-6-yl-1h-indazol-4-yl-2, 4-pyrimidine diamine
US7582122B2 (en) 2005-08-26 2009-09-01 L'oreal S.A. Mixed cationic dyes comprising at least one anthraquinone chromophore and their use in methods of hair dyeing
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
FR2893941A1 (fr) * 2005-11-25 2007-06-01 Sanofi Aventis Sa Nouveaux derives de 2,4-dianilinopyridines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
US7820648B2 (en) 2005-12-21 2010-10-26 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US8563549B2 (en) 2006-01-20 2013-10-22 Novartis Ag Pyrimidine derivatives used as PI-3 kinase inhibitors
US8217035B2 (en) 2006-01-20 2012-07-10 Novartis Ag Pyrimidine derivatives used as PI-3-kinase inhibitors
US20110046108A1 (en) * 2006-01-26 2011-02-24 Astrazeneca Ab Pyrimidine derivatives
JP2009525337A (ja) * 2006-01-30 2009-07-09 エクセリクシス， インク． Ｊａｋ−２調節因子としての４−アリール−２−アミノ−ピリミジン類又は４−アリール−２−アミノアルキル−ピリミジン類と使用方法
WO2007098507A2 (fr) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions et méthodes destinées à l'inhibition de la voie jak
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US11667611B2 (en) 2006-02-24 2023-06-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
US8258129B2 (en) * 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
JP2009542604A (ja) * 2006-07-06 2009-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
US8552186B2 (en) 2006-10-23 2013-10-08 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors
US8039479B2 (en) 2006-12-08 2011-10-18 Irm Llc Compounds and compositions as protein kinase inhibitors
US8377921B2 (en) 2006-12-08 2013-02-19 Irm Llc Compounds and compositions as protein kinase inhibitors
US8372858B2 (en) 2006-12-08 2013-02-12 Irm Llc Compounds and compositions as protein kinase inhibitors
US8399450B2 (en) 2006-12-08 2013-03-19 Irm Llc Compounds and compositions as protein kinase inhibitors
US8957081B2 (en) 2006-12-08 2015-02-17 Irm Llc Compounds and compositions as protein kinase inhibitors
US8173647B2 (en) 2007-02-06 2012-05-08 Gordana Atallah PI 3-kinase inhibitors and methods of their use
WO2008111441A1 (fr) 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. Composition pharmaceutique
JP2010524952A (ja) * 2007-04-16 2010-07-22 ハッチソン メディファーマ エンタープライジズ リミテッド ピリミジン誘導体
US8247411B2 (en) 2007-04-18 2012-08-21 Pfizer Inc Sulfonyl amide derivatives for the treatment of abnormal cell growth
US10450297B2 (en) 2007-04-18 2019-10-22 Pfizer, Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
WO2008129380A1 (fr) 2007-04-18 2008-10-30 Pfizer Products Inc. Dérivés de sulfonyle amide pour le traitement d'une croissance cellulaire anormale
US7928109B2 (en) 2007-04-18 2011-04-19 Pfizer Inc Sulfonyl amide derivatives for the treatment of abnormal cell growth
US8440822B2 (en) 2007-04-18 2013-05-14 Michael Joseph Luzzio Sulfonyl amide derivatives for the treatment of abnormal cell growth
CN101765591B (zh) * 2007-07-26 2013-11-27 诺华股份有限公司 用于治疗炎性或过敏性病症的嘧啶衍生物
US8067588B2 (en) 2007-10-09 2011-11-29 Dow Agrosciences Llc Insecticidal (1,3,5)-triazinyl phenyl hydrazones
US8507671B2 (en) 2007-10-09 2013-08-13 Dow Agrosciences Llc Insecticidal substituted azinyl derivatives
US8598182B2 (en) 2007-10-09 2013-12-03 Dow Agrosciences, Llc. Insecticidal pyrimidinyl aryl hyrdrazones
US8188273B2 (en) 2007-10-09 2012-05-29 Dow Agrosciences, Llc. Insecticidal (1,3,5)-triazinyl phenyl hydrazones
US8058279B2 (en) 2007-10-09 2011-11-15 Dow Agrosciences Llc Insecticidal pyrimidinyl aryl hyrdrazones
US8013154B2 (en) 2007-10-09 2011-09-06 Niyaz Noormohamed M Insecticidal substituted azinyl derivatives
US8455649B2 (en) 2007-10-09 2013-06-04 Dow Agrosciences, Llc Insecticidal substituted azinyl derivatives
US8461147B2 (en) * 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
US20100305099A1 (en) * 2007-12-03 2010-12-02 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
US8273744B2 (en) 2008-02-04 2012-09-25 Mercury Therapeutics, Inc. AMPK modulators
US8309566B2 (en) 2008-02-15 2012-11-13 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US8735418B2 (en) 2008-02-15 2014-05-27 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US9624229B2 (en) 2008-02-15 2017-04-18 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
WO2009136995A2 (fr) 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibiteurs de la syk protéine kinase
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8501944B2 (en) 2008-04-16 2013-08-06 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US11414410B2 (en) 2008-04-16 2022-08-16 Alexion Pharmaceuticals, Inc. Inhibitors of protein kinases
US9868729B2 (en) 2008-04-16 2018-01-16 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9579320B2 (en) 2008-04-16 2017-02-28 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8937070B2 (en) 2008-04-16 2015-01-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8952027B2 (en) 2008-04-16 2015-02-10 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US10533001B2 (en) 2008-04-16 2020-01-14 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9139581B2 (en) 2008-04-22 2015-09-22 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9296737B2 (en) 2008-06-27 2016-03-29 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US9409921B2 (en) 2008-06-27 2016-08-09 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines as kinase inhibitors
US10828300B2 (en) 2008-06-27 2020-11-10 Celgene Car Llc Substituted 2,4-diaminopyrimidines as kinase inhibitors
US10596172B2 (en) 2008-06-27 2020-03-24 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US10010548B2 (en) 2008-06-27 2018-07-03 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9987276B2 (en) 2008-06-27 2018-06-05 Celgene Car Llc Substituted 2,4-diaminopyrimidines as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9212181B2 (en) 2008-06-27 2015-12-15 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
EP2161259A1 (fr) 2008-09-03 2010-03-10 Bayer CropScience AG 4-haloalkyle-diaminopyrimidines substitués
US8377943B2 (en) 2008-11-14 2013-02-19 Boehringer Ingelheim International Gmbh 2,4-diaminopyrimidine derivates as PTK2-inhibitors for the treatment of abnormal cell growth
WO2010072155A1 (fr) * 2008-12-26 2010-07-01 复旦大学 Dérivé de pyrimidine, sa méthode de synthèse et ses applications
US8809343B2 (en) 2008-12-26 2014-08-19 Fudan University Pyrimidine derivative, preparation method and use thereof
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
CN102459236B (zh) * 2009-05-27 2014-10-29 Abbvie公司 激酶活性的嘧啶抑制剂
US8486933B2 (en) 2009-05-27 2013-07-16 Abbvie Inc. Pyrimidine inhibitors of kinase activity
WO2010138578A1 (fr) * 2009-05-27 2010-12-02 Abbott Laboratories Inhibiteurs pyrimidines de l'activité kinase
CN102459236A (zh) * 2009-05-27 2012-05-16 雅培制药有限公司 激酶活性的嘧啶抑制剂
CN102448943A (zh) * 2009-05-29 2012-05-09 贝林格尔.英格海姆国际有限公司 用于治疗特征在于过度或异常细胞增殖的疾病的2,4-二氨基嘧啶
WO2010136559A1 (fr) * 2009-05-29 2010-12-02 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidines pour le traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale
US8410126B2 (en) 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
US9096624B2 (en) 2009-06-01 2015-08-04 OSI Pharmaceuticals, LLC Amino pyrimidine anticancer compounds
CN102471287A (zh) * 2009-08-14 2012-05-23 贝林格尔.英格海姆国际有限公司 2-氨基-5-三氟甲基嘧啶衍生物的区域选择性制备方法
WO2011018518A1 (fr) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Préparation régiosélective de dérivés de 2-amino-5trifluorométhylpyrimidine
WO2011018517A1 (fr) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Préparation régiosélective de dérivés de 2-amino-5-trifluorométhylpyrimidine
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
JP2013501758A (ja) * 2009-08-14 2013-01-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8173808B2 (en) 2009-12-30 2012-05-08 Arqule, Inc. Substituted naphthalenyl-pyrimidine compounds
WO2011144742A1 (fr) 2010-05-21 2011-11-24 Chemilia Ab Nouveaux dérivés de pyrimidine
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
JP2013526562A (ja) * 2010-05-21 2013-06-24 ケミリア・エービー 新規ピリミジン誘導体
US8354420B2 (en) 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
US8785630B2 (en) 2010-07-20 2014-07-22 Vestaron Corporation Insecticidal triazines and pyrimidines
US9604936B2 (en) 2010-08-10 2017-03-28 Celgene Car Llc Besylate salt of a BTK inhibitor
US9867824B2 (en) 2010-11-01 2018-01-16 Celgene Car Llc Heterocyclic compounds and uses thereof
US10081606B2 (en) 2010-11-01 2018-09-25 Celgene Car Llc Heteroaryl compounds and uses thereof
EP3176154A1 (fr) 2010-11-01 2017-06-07 Portola Pharmaceuticals, Inc. Benzamides et nicotinamides en tant que modulateurs de syk
US10434101B2 (en) 2010-11-01 2019-10-08 Celgene Car Llc Heterocyclic compounds and uses thereof
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
WO2012061415A1 (fr) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Oxypyrimidines en tant que modulateurs de syk
WO2012061418A2 (fr) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Benzamides et nicotinamides en tant que modulateurs de syk
US9375431B2 (en) 2010-11-01 2016-06-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US11096942B2 (en) 2010-11-01 2021-08-24 Celgene Car Llc Heterocyclic compounds and uses thereof
US9102625B2 (en) 2010-11-01 2015-08-11 Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators
US9765038B2 (en) 2010-11-01 2017-09-19 Celgene Car Llc Heteroaryl compounds and uses thereof
US10391094B2 (en) 2010-11-07 2019-08-27 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis
US9868723B2 (en) 2010-11-10 2018-01-16 Celgene Car Llc Mutant-selective EGFR inhibitors and uses thereof
US8815882B2 (en) 2010-11-10 2014-08-26 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
US9409887B2 (en) 2010-11-10 2016-08-09 Celgene Avilomics Research, Inc. Mutant-selective EGFR inhibitors and uses thereof
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
WO2012101013A1 (fr) 2011-01-28 2012-08-02 Boehringer Ingelheim International Gmbh Pyridinyl-pyrimidines substituées et leur utilisation en tant que médicaments
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
EP2502924A1 (fr) 2011-03-24 2012-09-26 Chemilia AB Nouveaux dérivés de pyrimidine
WO2012127032A1 (fr) 2011-03-24 2012-09-27 Chemilia Ab Nouveaux dérivés de pyrimidine
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
US9000007B2 (en) 2011-09-27 2015-04-07 Dr. Reddy's Laboratories Ltd. 5-benzylaminomethyl-6-aminopyrazolo [3, 4 -B] pyridine derivatives as cholesteryl ester-transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
US8957068B2 (en) 2011-09-27 2015-02-17 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US9359308B2 (en) 2011-11-23 2016-06-07 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
JP2013112658A (ja) * 2011-11-30 2013-06-10 Toray Ind Inc Ｎ−（ヨードフェニル）ピリミジニルアミン誘導体の製造方法
US9458177B2 (en) 2012-02-24 2016-10-04 Novartis Ag Oxazolidin-2-one compounds and uses thereof
US8865894B2 (en) 2012-02-24 2014-10-21 Novartis Ag Oxazolidin-2-one compounds and uses thereof
US8697715B2 (en) 2012-03-01 2014-04-15 Array Biopharma, Inc. Serine/threonine kinase inhibitors
US10519126B2 (en) 2012-03-01 2019-12-31 Array Biopharma Inc. Serine/threonine kinase inhibitors
US9708290B2 (en) 2012-03-01 2017-07-18 Array Biopharma Inc. Serine/threonine kinase inhibitors
US9259470B2 (en) 2012-03-01 2016-02-16 Array Biopharma Inc. Serine/threonine kinase inhibitors
US10946016B2 (en) 2012-03-15 2021-03-16 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US9540335B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US9539255B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US10570099B2 (en) 2012-03-15 2020-02-25 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US10004741B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US10005738B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US11292772B2 (en) 2012-03-15 2022-04-05 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9834571B2 (en) 2012-05-05 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9388171B2 (en) 2012-08-27 2016-07-12 Genetech, Inc. Serine/threonine kinase inhibitors
EP2711364A1 (fr) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl ou benzimidazolyl)amino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer
EP2711365A1 (fr) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer
WO2014044754A1 (fr) 2012-09-21 2014-03-27 Chemilia Ab 4-indazolylamino -2- (2- (indol-3-yl) éthyl) aminopyrimidines utiles pour le traitement du cancer
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
US10202371B2 (en) 2012-11-12 2019-02-12 Novartis Ag Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9549927B2 (en) 2012-12-21 2017-01-24 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9504686B2 (en) 2013-02-08 2016-11-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9980964B2 (en) 2013-02-08 2018-05-29 Celgene Car Llc ERK inhibitors and uses thereof
US9796700B2 (en) 2013-02-08 2017-10-24 Celgene Car Llc ERK inhibitors and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
WO2014126954A1 (fr) * 2013-02-13 2014-08-21 OSI Pharmaceuticals, LLC Synthèse régiosélective de pyrimidines substituées
US10112931B2 (en) 2013-03-14 2018-10-30 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9688672B2 (en) 2013-03-14 2017-06-27 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9434719B2 (en) 2013-03-14 2016-09-06 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP2017510643A (ja) * 2014-03-28 2017-04-13 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
US9399637B2 (en) 2014-03-28 2016-07-26 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US9394281B2 (en) 2014-03-28 2016-07-19 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US9403801B2 (en) 2014-03-28 2016-08-02 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US10202364B2 (en) 2014-08-13 2019-02-12 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10059689B2 (en) 2014-10-14 2018-08-28 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN104529904A (zh) * 2015-01-09 2015-04-22 苏州明锐医药科技有限公司 玻玛西尼的制备方法
WO2016110224A1 (fr) * 2015-01-09 2016-07-14 苏州明锐医药科技有限公司 Procédé de préparation de bémaciclib
US9969718B2 (en) 2015-01-09 2018-05-15 Suzhou Miracpharma Technology Co., Ltd. Preparation method for Bemaciclb
US20180339979A1 (en) * 2015-04-01 2018-11-29 Rigel Pharmaceuticals, Inc. TGF-ß Inhibitors
US11021468B2 (en) * 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
CN106188038A (zh) * 2015-06-01 2016-12-07 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
WO2016192630A1 (fr) * 2015-06-01 2016-12-08 中国科学院上海药物研究所 Composé présentant une activité inhibitrice de kinase, son procédé de préparation, et utilisation de celui-ci
CN104910049A (zh) * 2015-06-16 2015-09-16 苏州明锐医药科技有限公司 Azd9291中间体及其制备方法
CN105130907A (zh) * 2015-07-29 2015-12-09 沈阳药科大学 嘧啶类化合物及其用途
US10266521B2 (en) 2015-09-11 2019-04-23 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2017114510A1 (fr) * 2015-12-31 2017-07-06 中国科学院上海药物研究所 Composé présentant une activité inhibitrice de l'erk kinase, son procédé de préparation et utilisation associée
US11001569B2 (en) 2016-01-22 2021-05-11 Janssen Pharmaceutica Nv 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
KR102784966B1 (ko) 2016-01-22 2025-03-20 잔센파마슈티카엔.브이. Nik 억제제로서 신규 치환된 시아노인돌린 유도체
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
KR20180100441A (ko) * 2016-01-22 2018-09-10 잔센파마슈티카엔.브이. Nik 억제제로서 신규 치환된 시아노인돌린 유도체
JP2019504067A (ja) * 2016-01-22 2019-02-14 ジャンセン ファーマシューティカ エヌブイ Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体
JP2019502714A (ja) * 2016-01-22 2019-01-31 ジャンセン ファーマシューティカ エヌブイ Ｎｉｋ阻害剤としての新たな６員のヘテロ芳香族置換シアノインドリン誘導体
KR20180098679A (ko) * 2016-01-22 2018-09-04 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
WO2017125534A1 (fr) * 2016-01-22 2017-07-27 Janssen Pharmaceutica Nv Nouveaux dérivés de cyanoindoline à substitution hétéroaromatique à 6 chaînons utilisés comme inhibiteurs de nik
US11180487B2 (en) 2016-01-22 2021-11-23 Janssen Pharmaceutica Nv Substituted cyanoindoline derivatives as NIK inhibitors
WO2017125530A1 (fr) * 2016-01-22 2017-07-27 Janssen Pharmaceutica Nv Nouveaux dérivés de cyanoindoline utilisés comme inhibiteurs de nik
CN107151233A (zh) * 2016-03-03 2017-09-12 沈阳药科大学 含腙的嘧啶类衍生物及其用途
EA037358B1 (ru) * 2016-03-10 2021-03-17 Янссен Фармасьютика Нв Новые замещённые производные цианиндолина в качестве nik-ингибиторов
WO2017211268A1 (fr) * 2016-06-07 2017-12-14 上海宣创生物科技有限公司 Forme cristalline a, forme cristalline b et forme cristalline c de bemaciclib et procédé de préparation correspondant
US11186589B2 (en) 2016-06-30 2021-11-30 Janssen Pharmaceutica Nv Cyanoindoline derivatives as NIK inhibitors
WO2018002219A1 (fr) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Nouveaux dérivés de cyanoindoline comme inhibiteurs de nik
US11136311B2 (en) 2016-06-30 2021-10-05 Janssen Pharmaceutica Nv Heteroaromatic derivatives as NIK inhibitors
CN109689645B (zh) * 2016-06-30 2022-06-03 杨森制药有限公司 作为nik抑制剂的氰基吲哚啉衍生物
CN109689645A (zh) * 2016-06-30 2019-04-26 杨森制药有限公司 作为nik抑制剂的氰基吲哚啉衍生物
WO2018002217A1 (fr) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Dérivés hétéroaromatiques en tant qu'inhibiteurs de nik
JP2019524646A (ja) * 2016-06-30 2019-09-05 ジャンセン ファーマシューティカ エヌブイ Ｎｉｋ阻害剤としてのシアノインドリン誘導体
US12006302B2 (en) 2016-07-18 2024-06-11 Janssen Pharmaceutica Nv Tau PET imaging ligands
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
CN107652273A (zh) * 2016-07-26 2018-02-02 沈阳药科大学 嘧啶类衍生物及其制备方法和应用
CN107652273B (zh) * 2016-07-26 2020-05-01 沈阳药科大学 嘧啶类衍生物及其制备方法和应用
CN107868082A (zh) * 2016-09-22 2018-04-03 上海宣创生物科技有限公司 玻玛西尼甲磺酸盐a晶型及其制备方法
US11390609B2 (en) 2017-06-30 2022-07-19 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
US10323023B2 (en) 2017-06-30 2019-06-18 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
WO2019008011A1 (fr) 2017-07-06 2019-01-10 Janssen Pharmaceutica Nv Nouveaux dérivés d'azaindoline substitués utilisés en tant qu'inhibiteurs de nik
US11236084B2 (en) 2017-07-06 2022-02-01 Janssen Pharmaceutica Nv Substituted azaindoline derivatives as NIK inhibitors
US20190023666A1 (en) * 2017-07-18 2019-01-24 GiraFpharma LLC Heterocyclic compounds as adenosine antagonists
US11028058B2 (en) * 2017-07-18 2021-06-08 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
US10793561B2 (en) 2017-07-18 2020-10-06 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2019200502A1 (fr) * 2018-04-16 2019-10-24 杭州领业医药科技有限公司 Forme cristalline de mésylate d'abémaciclib, procédé de préparation et composition pharmaceutique associés
CN108503623A (zh) * 2018-05-11 2018-09-07 四川大学 一种抑制prmt7的化合物及其制备方法与应用
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
US11306071B2 (en) 2019-01-18 2022-04-19 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11518758B2 (en) 2019-05-10 2022-12-06 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
US11530206B2 (en) 2019-05-10 2022-12-20 Deciphera Pharmaceuticals, Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
US12071432B2 (en) 2019-05-10 2024-08-27 Deciphera Pharmaceuticals, Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
US11590134B2 (en) 2019-06-17 2023-02-28 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US12312331B2 (en) 2019-08-14 2025-05-27 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
CN110669038A (zh) * 2019-09-21 2020-01-10 温州医科大学 一种嘧啶类fgfr4v550l抑制剂及其制备方法和应用
CN110746402A (zh) * 2019-09-21 2020-02-04 温州医科大学 一种2-n-芳基-4-n-芳基-5-氟嘧啶类化合物及其制备方法和应用
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN111423419B (zh) * 2020-01-17 2021-12-17 温州医科大学 一种小分子化合物cyy-260及其在制备抗肿瘤药物中的应用
CN111423419A (zh) * 2020-01-17 2020-07-17 温州医科大学 一种小分子化合物cyy-260及其在制备抗肿瘤药物中的应用
CN111484484A (zh) * 2020-04-13 2020-08-04 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024182751A1 (fr) * 2023-03-02 2024-09-06 Sionna Therapeutics Inc. Modulateurs de nbd1 et leurs procédés d'utilisation

Similar Documents

Publication Publication Date Title
WO2003030909A1 (fr) 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
RU2734418C2 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
EP2137166B1 (fr) Dérivés d'aminopyrimidines 4,6 disubstitués comme inhibiteurs de protéine kinase
AU2006335967B2 (en) Novel heterocycles
ES2703997T3 (es) Nuevos derivados de aminoácidos, un proceso para su preparación y composiciones farmacéuticas que los contienen
JP4948173B2 (ja) 過剰増殖性疾患治療用ピリミジン誘導体
US20060069110A1 (en) Substituted heterocyclic compounds and methods of use
EP0850228A1 (fr) Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires
JP2007502260A (ja) 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
MXPA02008240A (es) Moduladores del receptor de adenosina.
EP1701944B1 (fr) 2-(amino-substituees)-4-aryl pyramidines et composes associes utiles dans le traitement de maladies inflammatoires
WO2006014482A1 (fr) Dérivés de pyrimidine utiles comme inhibiteurs de la pkc-thêta
MX2007010102A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos.
PL170373B1 (pl) Sposób wytwarzania nowych, podstawionych 5-arylopirymidyn PL PL PL
US20110294838A1 (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
CA2590250A1 (fr) Inhibiteurs de la proteine kinase erk et utilisations
WO2003057689A1 (fr) Composes aminopyrimidine, procedes de preparation de ces composes et compositions pharmaceutiques les contenant
US20050222412A1 (en) Peptide deformylase inhibitors
KR100835770B1 (ko) 엔도텔린 길항 활성을 갖는 아릴알칸-설폰아마이드
Goto et al. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors
KR101379808B1 (ko) 산화질소 생성 억제용 피라졸로피리미딘 유도체 화합물
AU2009208712B2 (en) Novel heterocycles
CA2645728A1 (fr) Derives de phtalazinone pyrazole, leur fabrication et leur utilisation comme agents pharmaceutiques
WO2005037801A1 (fr) Compose pyrimidine
EP2760843B1 (fr) Antagonistes du nr2b sélectifs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PH PL PT RO SD SE SG SI SK SL TJ TM TR TT TZ UG US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载